Dr
Évelyne DRAPIER-FAURE
Publications
récentes
Faure
M, Drapier-Faure E.Nouveaux contraceptifs. Ann Dermatol Venereol. 2006 Mar;133(3):292-5
Drapier-Faure
E. [HRT: abandon? Menopausal hormone replacement: future]. Gynecol Obstet Fertil.
2005 Nov;33(11):847-50. Epub 2005 Oct 21
Nguyên-Pascal
ML, Thomas JL, Bergougnoux L, Garnero P, Drapier-Faure E, Delmas PD. Nomegestrol
acetate may enhance the skeletal effects of estradiol on biochemical markers of
bone turnover in menopausal women after a 12-week treatment period. Climacteric.
2005 Jun;8(2):136-45.
Drapier-Faure
E, Azoulay C, Abramovici Y. [Acceptability of continuous combined versus cyclical
HRT: a French multicentric randomized clinical study]
Gynecol Obstet Fertil.
2005 Jul-Aug;33(7-8):498-504. French.
Drapier-Faure
E.
[There
are reasons to continue hormone replacement therapy longer than 10 years]
Gynecol
Obstet Fertil. 2003 Feb;31(2):189-90; author reply 193-4. French. No abstract
available.
Faure
M, Drapier-Faure E. Traiement hormonaux de l'acné. Ann Dermatol Venereol.
2003 Jan;130(1 Pt 2):142-7. Review. French. No abstract available.
Drapier-Faure
E. Il y a des raisons de poursuivre un traitement hormonal substitutif au-delà
d'une durée de 10 ans. Gynécologie Obstétrique & Fertilité
2003:31(2)189
Drapier-Faure
E, Faure M. What is the role of hormonal treatments in acne? Ann Dermatol Venereol.
2001;128 Supp 1:S19-24
Drapier-Faure
E. Phytoestrogens. Therapeutic use Gynecol Obstet Fertil. 2001;29(2):141-7
Faure
M, Drapier-Faure E. Lupus and pregnancy. Ann Dermatol Venereol. 2000;127(1):101-3
Drapier-Faure
E. For or against non-stop hormone replacement therapy? Contracept Fertil Sex.
1999;27(3):183-6
Faure
M, Drapier-Faure E. Managing hyperandrogenism. Ann Dermatol Venereol. 1998;125(8):533-40
Faure
M, Drapier-Faure E. Vulvovaginitis Rev Prat. 1997;47(15):1655-60
Drapier-Faure
E. Choice and follow-up of contraception without risk factor Rev Prat. 1995;45(19):2417-21
Gillet
JY, Andre G, Faguer B, Erny R, Buvat-Herbaut M, Domin MA, Kuhn JM, Hedon B, Drapier-Faure
E, Barrat J, et al. Induction of amenorrhea during hormone replacement therapy:
optimal micronized progesterone dose. A multicenter study. Maturitas. 1994;19(2):103-15
Drapier-Faure
E. The risk of hormone therapy in women with vascular risks Contracept Fertil
Sex. 1994;22(7-8):429-33
Drapier-Faure
E. Menopause. Diagnosis, treatment Rev Prat. 1993;43(7):917-22
Drapier-Faure
E. Inconveniences and risks of untreated menopause. Benefits brought by the replacement
hormonal treatment Rev Fr Gynecol Obstet. 1992;87(7-9):393-6
Faure
M, Drapier-Faure E. Hormonal assessment in a woman with acne and alopecia Rev
Fr Gynecol Obstet. 1992 ;87(6):331-4
Drapier-Faure
E. Purified FSH in small doses. Is this not the best current treatment of polycystic
ovaries resistant to clomid? 73 cycles J Gynecol Obstet Biol Reprod (Paris).
1991;20(5):651-5
Drapier-Faure
E. Prevention of iatrogenic hyperandrogenism Rev Fr Gynecol Obstet. 1989;84(6):535-7
Drapier-Faure
E. An evaluation of sterility today Rev Fr Gynecol Obstet. 1988 15;83(6):397-400
Bremond
A, Ollier V, Drapier-Faure E. Thermography of the breast. Sensitivity, specificity
and reproducibility Bull Cancer. 1988;75(2):183-6
